<DOC>
	<DOCNO>NCT02826928</DOCNO>
	<brief_summary>Urinary measure 5-hydroxyindolacetic acid ( 5HIAA ) important marker diagnosis follow-up patient small-intestine neuroendocrine tumor . Although marker good specificity , sensitivity moderate dosage constraining , since require urine collection 2-3 day specific diet . Preliminary data suggest overnight 5HIAA value may representative 24-hour 5HIAA value , plasma 5HIAA dosage could valuable alternative urine 5HIAA dosage . The main objective study compare sensitivity specificity overnight 5HIAA value , 24-hour 5HIAA value plasma 5HIAA value , patient small-intestine neuroendocrine tumor .</brief_summary>
	<brief_title>Diagnostic Performances Urine Plasma 5-hydroxyindolacetic Acid ( 5HIAA ) Values Patients With Small-intestine Neuroendocrine Tumors</brief_title>
	<detailed_description>This study primarily aim compare sensitivity specificity overnight 5HIAA value , 24-hour 5HIAA value plasma 5HIAA value , patient small-intestine neuroendocrine tumor . Secondary objective include correlation 5HIAA value chromogranin A , carcinoid syndrome tumor burden evaluation compliance diet correlation 5HIAA value . The study group include patient proven neuroendocrine tumor various stage function syndrome profile . A control group constitute subject irritable bowel syndrome , neuroendocrine tumor rule . After provide informed consent , patient fit inclusion criterion include study . Patients follow specific diet , interrupt/avoid certain medication , 2 day 2 day sample period . Whole urine sample collect 2 consecutive day , 4 part ( day1 , night 1 , day 2 , night 2 ) . Blood sample collect morning day 2 3 . Observance diet drug restriction evaluate morning day 3 .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<criteria>Inclusion criterion : Histologically proven smallintestine neuroendocrine tumor , initial diagnosis followup Irritable bowel syndrome , diagnose follow Rome III criterion , ileocolonoscopy abdominal CTscan within 12 last month Age &gt; 18 year No antitumor treatment within last three month except somatostatin analog Ability understand approve study protocol provide write consent Affiliation French Health Social System Exclusion criterion Smallintestine neuroendocrine tumor remission ( detectable disease ) Other malignancy smallintestine neuroendocrine tumor ( except remission 2 year ) Kidney insufficiency ( MDRD &lt; 60/min ) Urinary incontinency inability collect urine Any antitumor treatment within last three month except somatostatin analog Inability interrupt treatment interfere 5HIAA dosage Pregnancy Patients law protection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>